EirGenix Inc. (TPE:6589)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
46.25
-1.05 (-2.22%)
At close: Jul 16, 2026
Market Cap14.33B -21.8%
Revenue (ttm)1.13B +16.5%
Net Income-745.70M
EPS-2.47
Shares Out 302.88M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume771,817
Open47.50
Previous Close47.30
Day's Range46.25 - 48.20
52-Week Range40.15 - 84.30
Beta0.34
Analystsn/a
Price Targetn/a
Earnings DateAug 13, 2026

About EirGenix

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and curr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 1,000
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6589
Full Company Profile

Financial Performance

In 2025, EirGenix's revenue was 1.01 billion, a decrease of -0.38% compared to the previous year's 1.01 billion. Losses were -760.55 million, 8.91% more than in 2024.

Financial Statements